看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。+ p9 V6 T/ ~' I
$ c; _5 ^' T, C; |" W$ W: s5 X4 k
Currently available feasibility data for possible combination strategies.
! [5 u* |2 x# Q————————————————————————————————# `6 z/ A% i) a2 B
Combination Feasibility according to preliminary data
6 y) S+ }8 r; z1 a——————————————————————————————————
+ V/ a2 N- _: K- J( ~( e4 ZBevacizumab + sorafenib Yes, reduced dose
/ y& I) i! u T( O) f. C7 ABevacizumab + sunitinib† No 3 P1 i+ k) a7 b" V$ ~
Bevacizumab + temsirolimus Yes
+ E6 h' {2 R8 UBevacizumab + everolimus Yes
% B- p. g+ _0 aSorafenib + sunitinib ? S" q. u5 G! Z; G/ [. v
Sorafenib + temsirolimus Yes, reduced dose 5 N& D8 |4 g, }3 ]% T5 w+ \
Sorafenib + everolimus Yes, reduced dose
" R5 I+ A" \6 w; ~5 @Sunitinib + temsirolimus† No ) c3 n M6 s) \5 c6 A
Sunitinib + everolimus ? 8 [, A/ P/ q v( u, d2 g# f
Temsirolimus + everolimus ? % s% R$ d7 s% `( [, z' h E9 Q
————————————————————6 u* h# \% l) j+ x
†Led to US FDA warning.
% ~+ z8 {) J1 U m8 V?: As yet unattempted combination.' p. ?' E Q: ]4 U0 `+ E7 U R
|
显身卡
7 D4 e) P3 t; F g. {; A+ o
